QIAGEN N.V. develops Sample to Insight technologies for extracting, purifying, amplifying and interpreting DNA, RNA and proteins. Its recurring news covers life sciences and molecular diagnostics applications, including sample technologies, assay technologies, bioinformatics and laboratory automation used in clinical healthcare, pharmaceutical research, academia, forensics and other research settings.
Company updates frequently address product and regulatory developments across QuantiFERON tuberculosis testing, QIAstat-Dx syndromic testing panels, QIAcuity digital PCR, QIAGEN Digital Insights and automated sample-preparation systems such as QIAsymphony and QIAstat-Dx Rise. Financial news also tracks sales trends across consumables, instruments and services, profitability measures, capital-return actions, acquisitions, and changes affecting portfolio growth areas.
QIAGEN N.V. (NYSE: QGEN) announced preliminary Q2 2021 results and updated its full-year outlook. A conference call is set for July 13, 2021, at 15:00 CET / 9:00 EDT, hosted by CEO Thierry Bernard and CFO Roland Sackers. Stakeholders can join by dialing +1 929 477 0402 (U.S.) or other regional numbers. The company continues to provide Sample to Insight solutions for over 500,000 customers globally across molecular diagnostics and life sciences sectors.
QIAGEN N.V. (NYSE: QGEN) announced strong preliminary results for Q2 2021, with net sales up 28% to $567.3 million, exceeding the expected 20% growth. Adjusted EPS rose about 21% to $0.66-0.67, surpassing projections. Non-COVID product sales surged 52% to $407.6 million, making up 72% of total sales, while COVID-19 product sales declined 17% to $159.7 million due to increased vaccination rates. The company revealed plans for a $100 million share repurchase program to enhance shareholder value, reflecting confidence in future growth.
QIAGEN N.V. (NYSE: QGEN) has announced CE-IVD certification for its NeuMoDx™ HAdV Quant Assay, which identifies and quantifies human adenovirus DNA. This assay is the 15th addition to the NeuMoDx 96 and 288 Molecular Systems, enabling critical testing for immunocompromised patients. Developed with Sentinel Diagnostics, the assay enhances QIAGEN's offerings in transplant health by complementing existing tests for CMV, EBV, and BKV. The NeuMoDx systems provide a comprehensive portfolio, supporting various viral and bacterial pathogen testing.
QIAGEN N.V. (NYSE: QGEN) has launched the Workflow Configurator, a cloud-based tool designed to help life sciences researchers optimize their experiments. This application allows users to select applications, biological materials, and analytes, quickly identifying suitable products from QIAGEN's extensive portfolio. The configurator enhances efficiency by integrating with My QIAGEN and QIAGEN's Web Shop, enabling seamless workflow management. This launch is part of QIAGEN's strategy to digitalize its offerings, emphasizing the importance of digital tools in the life sciences industry.
QIAGEN (NYSE:QGEN) has entered a strategic alliance with Japan’s Sysmex Corporation to enhance cancer companion diagnostics leveraging QIAGEN’s expertise and Sysmex’s Plasma-Safe-SeqS technology. The partnership focuses on collaborating with pharmaceutical companies to develop drug treatments and promote liquid biopsy diagnostics. QIAGEN, a pioneer in precision medicine, boasts an extensive portfolio of FDA-approved diagnostic products and holds master collaboration agreements with over 25 companies. This alliance aims to improve clinical decision-making and patient outcomes in cancer treatment globally.
QIAGEN N.V. (NYSE: QGEN) has formed a strategic partnership with Verogen Inc. to enhance next-generation sequencing (NGS) tools for human identification workflows. This agreement grants QIAGEN global distribution rights for Verogen's products and involves collaboration on forensically validated NGS workflows. The partnership aims to provide laboratories with comprehensive solutions, optimizing QIAGEN’s sample prep automation alongside Verogen’s innovative NGS capabilities. This collaboration is expected to drive the adoption of NGS technology in forensic applications, improving insights from casework samples.
QIAGEN N.V. (NYSE: QGEN) announced a partnership with Verogen, enhancing its offerings in human identification workflows. This collaboration allows QIAGEN to distribute Verogen's sequencing solutions, including the ForenSeq assay and MiSeq FGx sequencing system, globally. Both companies will develop forensically validated workflows that combine their products and expertise. This partnership aims to accelerate the adoption of next-generation sequencing (NGS) in forensics, providing laboratories with improved tools for human identification. Financial terms were not disclosed.
QIAGEN (NYSE: QGEN) has launched the QIAprep CRISPR Kit and CRISPR Q-Primer Solutions, enhancing speed and efficiency in analyzing edited genetic material. This launch targets the booming CRISPR technology sector, crucial for gene editing and biomedical research. The new products facilitate a sensitive, all-in-one approach to analyze gene editing effects, reducing experimental time significantly. These solutions support various cell culturing methods and can be customized for targeted applications, potentially accelerating breakthroughs in areas like cancer therapy and drug development.
QIAGEN N.V. (QGEN) has launched an expanded scope of companion diagnostic claims for the therascreen KRAS RGQ PCR Kit, following FDA approval. This kit aids in identifying non-small cell lung cancer (NSCLC) patients eligible for Amgen's LUMAKRASTM treatment, targeting the KRAS G12C mutation, present in up to 13% of NSCLC cases. This approval marks a significant milestone in precision medicine, enhancing QIAGEN's therascreen portfolio and expanding testing availability through its Day-One Lab Readiness program.
QIAGEN N.V. announced a global collaboration with Mirati Therapeutics to develop a tissue-based KRAS companion diagnostic for cancers with the KRASG12C mutation, focusing initially on non-small cell lung cancer (NSCLC). This initiative expands QIAGEN's existing therascreen KRAS testing portfolio and leverages the company's decade-long expertise in companion diagnostics. QIAGEN holds a strong position in Precision Medicine and has ongoing collaborations with over 25 companies for companion diagnostic tests, indicating a robust pipeline for future product development.